Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors

Maureen A. Cooper, Lawrence Einhorn

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy. Patients and Methods: Thirty-seven patients were entered onto this trial, and 34 were fully assessable. This was a heavily pretreated patient population, with a median of two prior salvage regimens. The salvage treatment that immediately preceded oral VP-16 consisted of autologous bone marrow transplantation in 14 patients (41%), surgery in 10 (29%), and standard-dose salvage chemotherapy in 10 (29%). Daily oral VP-16 was administered at a dose of 50 mg/m2 for 21 consecutive days every 4 weeks for three cycles. Results: The major toxicity with daily oral VP-16 was leukopenia. Three patients had grade III and two grade IV leukopenia. Two of these patients had granulocytopenic fever. Other grade III toxicities included thrombocytopenia (n = 1) and mucositis (n = 2). Twenty-three patients started daily oral VP- 16 while in complete remission (CR) following salvage therapy. Seventeen (74%) remain continuously disease-free, with a median follow-up time of 36 months (range, 26 to 49) from initiation of daily oral VP-16. Eleven patients started daily oral VP-16 while in partial remission (PR) following salvage therapy. Three of these 11 patients converted to CR, but all three subsequently relapsed. Conclusion: Maintenance oral VP-16 was well tolerated in this heavily treated patient population. Results in this poor-risk population were encouraging.

Original languageEnglish
Pages (from-to)1167-1169
Number of pages3
JournalJournal of Clinical Oncology
Volume13
Issue number5
StatePublished - May 1995

Fingerprint

Maintenance Chemotherapy
Salvage Therapy
Germ Cell and Embryonal Neoplasms
Etoposide
Leukopenia
Maintenance
Population
Drug Therapy
Mucositis
Autologous Transplantation
Bone Marrow Transplantation
Germ Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. / Cooper, Maureen A.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 13, No. 5, 05.1995, p. 1167-1169.

Research output: Contribution to journalArticle

@article{98b0422c2081458092c2da6ea9554197,
title = "Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors",
abstract = "Purpose: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy. Patients and Methods: Thirty-seven patients were entered onto this trial, and 34 were fully assessable. This was a heavily pretreated patient population, with a median of two prior salvage regimens. The salvage treatment that immediately preceded oral VP-16 consisted of autologous bone marrow transplantation in 14 patients (41{\%}), surgery in 10 (29{\%}), and standard-dose salvage chemotherapy in 10 (29{\%}). Daily oral VP-16 was administered at a dose of 50 mg/m2 for 21 consecutive days every 4 weeks for three cycles. Results: The major toxicity with daily oral VP-16 was leukopenia. Three patients had grade III and two grade IV leukopenia. Two of these patients had granulocytopenic fever. Other grade III toxicities included thrombocytopenia (n = 1) and mucositis (n = 2). Twenty-three patients started daily oral VP- 16 while in complete remission (CR) following salvage therapy. Seventeen (74{\%}) remain continuously disease-free, with a median follow-up time of 36 months (range, 26 to 49) from initiation of daily oral VP-16. Eleven patients started daily oral VP-16 while in partial remission (PR) following salvage therapy. Three of these 11 patients converted to CR, but all three subsequently relapsed. Conclusion: Maintenance oral VP-16 was well tolerated in this heavily treated patient population. Results in this poor-risk population were encouraging.",
author = "Cooper, {Maureen A.} and Lawrence Einhorn",
year = "1995",
month = "5",
language = "English",
volume = "13",
pages = "1167--1169",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors

AU - Cooper, Maureen A.

AU - Einhorn, Lawrence

PY - 1995/5

Y1 - 1995/5

N2 - Purpose: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy. Patients and Methods: Thirty-seven patients were entered onto this trial, and 34 were fully assessable. This was a heavily pretreated patient population, with a median of two prior salvage regimens. The salvage treatment that immediately preceded oral VP-16 consisted of autologous bone marrow transplantation in 14 patients (41%), surgery in 10 (29%), and standard-dose salvage chemotherapy in 10 (29%). Daily oral VP-16 was administered at a dose of 50 mg/m2 for 21 consecutive days every 4 weeks for three cycles. Results: The major toxicity with daily oral VP-16 was leukopenia. Three patients had grade III and two grade IV leukopenia. Two of these patients had granulocytopenic fever. Other grade III toxicities included thrombocytopenia (n = 1) and mucositis (n = 2). Twenty-three patients started daily oral VP- 16 while in complete remission (CR) following salvage therapy. Seventeen (74%) remain continuously disease-free, with a median follow-up time of 36 months (range, 26 to 49) from initiation of daily oral VP-16. Eleven patients started daily oral VP-16 while in partial remission (PR) following salvage therapy. Three of these 11 patients converted to CR, but all three subsequently relapsed. Conclusion: Maintenance oral VP-16 was well tolerated in this heavily treated patient population. Results in this poor-risk population were encouraging.

AB - Purpose: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy. Patients and Methods: Thirty-seven patients were entered onto this trial, and 34 were fully assessable. This was a heavily pretreated patient population, with a median of two prior salvage regimens. The salvage treatment that immediately preceded oral VP-16 consisted of autologous bone marrow transplantation in 14 patients (41%), surgery in 10 (29%), and standard-dose salvage chemotherapy in 10 (29%). Daily oral VP-16 was administered at a dose of 50 mg/m2 for 21 consecutive days every 4 weeks for three cycles. Results: The major toxicity with daily oral VP-16 was leukopenia. Three patients had grade III and two grade IV leukopenia. Two of these patients had granulocytopenic fever. Other grade III toxicities included thrombocytopenia (n = 1) and mucositis (n = 2). Twenty-three patients started daily oral VP- 16 while in complete remission (CR) following salvage therapy. Seventeen (74%) remain continuously disease-free, with a median follow-up time of 36 months (range, 26 to 49) from initiation of daily oral VP-16. Eleven patients started daily oral VP-16 while in partial remission (PR) following salvage therapy. Three of these 11 patients converted to CR, but all three subsequently relapsed. Conclusion: Maintenance oral VP-16 was well tolerated in this heavily treated patient population. Results in this poor-risk population were encouraging.

UR - http://www.scopus.com/inward/record.url?scp=0029026302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026302&partnerID=8YFLogxK

M3 - Article

C2 - 7738621

AN - SCOPUS:0029026302

VL - 13

SP - 1167

EP - 1169

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -